In addition, increased methylation and epigenetic silencing of TREX1 are observed in patients with small cell lung cancer, and are associated with increased sensitivity of tumor cells to anti‐mitotic drugs, ATR, and CDK inhibitors.[10] Hence, the potential of TREX1 inhibitors remains to be determined. Here, TREX1 is linked to neoplasm.